$CBT
CABOT CORP

2021 Q4 Form 10-Q Financial Statement

#000156459022003902 Filed on February 04, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2020 Q4
Revenue $968.0M $746.0M
YoY Change 29.76% 2.61%
Cost Of Revenue $769.0M $550.0M
YoY Change 39.82% -6.14%
Gross Profit $199.0M $196.0M
YoY Change 1.53% 39.01%
Gross Profit Margin 20.56% 26.27%
Selling, General & Admin $70.00M $61.00M
YoY Change 14.75% 7.02%
% of Gross Profit 35.18% 31.12%
Research & Development $13.00M $14.00M
YoY Change -7.14% 0.0%
% of Gross Profit 6.53% 7.14%
Depreciation & Amortization $39.00M $39.00M
YoY Change 0.0% 0.0%
% of Gross Profit 19.6% 19.9%
Operating Expenses $83.00M $75.00M
YoY Change 10.67% 435.71%
Operating Profit $116.0M $121.0M
YoY Change -4.13% 92.06%
Interest Expense -$9.000M -$10.00M
YoY Change -10.0% -9.09%
% of Operating Profit -7.76% -8.26%
Other Income/Expense, Net -$1.000M -$9.000M
YoY Change -88.89% 350.0%
Pretax Income -$93.00M $99.00M
YoY Change -193.94% 98.0%
Income Tax -$12.00M $29.00M
% Of Pretax Income 29.29%
Net Earnings -$89.00M $60.00M
YoY Change -248.33% 46.34%
Net Earnings / Revenue -9.19% 8.04%
Basic Earnings Per Share -$1.57 $1.06
Diluted Earnings Per Share -$1.57 $1.06
COMMON SHARES
Basic Shares Outstanding 56.80M 56.50M
Diluted Shares Outstanding 56.80M 56.60M

Balance Sheet

Concept 2021 Q4 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $179.0M $147.0M
YoY Change 21.77% -15.03%
Cash & Equivalents $179.0M $147.0M
Short-Term Investments
Other Short-Term Assets $224.0M $62.00M
YoY Change 261.29% 5.08%
Inventory $546.0M $403.0M
Prepaid Expenses
Receivables $660.0M $513.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.609B $1.125B
YoY Change 43.02% -5.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.267B $1.353B
YoY Change -6.36% -3.01%
Goodwill $140.0M $134.0M
YoY Change 4.48% 45.65%
Intangibles
YoY Change
Long-Term Investments $14.00M $41.00M
YoY Change -65.85% 5.13%
Other Assets $158.0M $161.0M
YoY Change -1.86% -5.85%
Total Long-Term Assets $1.706B $1.855B
YoY Change -8.03% -5.12%
TOTAL ASSETS
Total Short-Term Assets $1.609B $1.125B
Total Long-Term Assets $1.706B $1.855B
Total Assets $3.315B $2.980B
YoY Change 11.24% -5.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $620.0M $521.0M
YoY Change 19.0% -0.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $226.0M $13.00M
YoY Change 1638.46% 225.0%
Long-Term Debt Due $373.0M $8.000M
YoY Change 4562.5% 14.29%
Total Short-Term Liabilities $1.327B $570.0M
YoY Change 132.81% -0.7%
LONG-TERM LIABILITIES
Long-Term Debt $714.0M $1.085B
YoY Change -34.19% -0.91%
Other Long-Term Liabilities $253.0M $305.0M
YoY Change -17.05% 5.54%
Total Long-Term Liabilities $967.0M $1.390B
YoY Change -30.43% 0.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.327B $570.0M
Total Long-Term Liabilities $967.0M $1.390B
Total Liabilities $2.521B $1.960B
YoY Change 28.62% 0.1%
SHAREHOLDERS EQUITY
Retained Earnings $1.049B $1.032B
YoY Change 1.65% -22.35%
Common Stock $11.00M $57.00M
YoY Change -80.7% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $794.0M $823.0M
YoY Change
Total Liabilities & Shareholders Equity $3.315B $2.980B
YoY Change 11.24% -5.43%

Cashflow Statement

Concept 2021 Q4 2020 Q4
OPERATING ACTIVITIES
Net Income -$89.00M $60.00M
YoY Change -248.33% 46.34%
Depreciation, Depletion And Amortization $39.00M $39.00M
YoY Change 0.0% 0.0%
Cash From Operating Activities -$49.00M $21.00M
YoY Change -333.33% -80.0%
INVESTING ACTIVITIES
Capital Expenditures $30.00M $29.00M
YoY Change 3.45% -57.35%
Acquisitions
YoY Change
Other Investing Activities -$1.000M
YoY Change
Cash From Investing Activities -$29.00M -$29.00M
YoY Change 0.0% -62.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.00M $1.000M
YoY Change 1800.0% -96.97%
Debt Paid & Issued, Net $5.000M $66.00M
YoY Change -92.42% 37.5%
Cash From Financing Activities 103.0M -38.00M
YoY Change -371.05% -13.64%
NET CHANGE
Cash From Operating Activities -49.00M 21.00M
Cash From Investing Activities -29.00M -29.00M
Cash From Financing Activities 103.0M -38.00M
Net Change In Cash 10.00M -4.000M
YoY Change -350.0% -200.0%
FREE CASH FLOW
Cash From Operating Activities -$49.00M $21.00M
Capital Expenditures $30.00M $29.00M
Free Cash Flow -$79.00M -$8.000M
YoY Change 887.5% -121.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
197000000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-80000000
CY2020Q4 us-gaap Profit Loss
ProfitLoss
70000000
CY2021Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
9000000
CY2020Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
10000000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-89000000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
60000000
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56800000
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56500000
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56800000
CY2020Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56600000
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.06
CY2021Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-28000000
CY2020Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
94000000
CY2021Q4 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
1000000
CY2020Q4 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
1000000
CY2021Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-1000000
CY2020Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-3000000
CY2020Q4 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-3000000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28000000
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
96000000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-108000000
CY2020Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
166000000
CY2021Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
2000000
CY2020Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
7000000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
11000000
CY2020Q4 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
17000000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-119000000
CY2020Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
149000000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179000000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168000000
CY2021Q4 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
4000000
CY2021Q3 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
4000000
CY2021Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
660000000
CY2021Q3 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
645000000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
154000000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
168000000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
341000000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
300000000
CY2021Q4 us-gaap Other Inventory
OtherInventory
51000000
CY2021Q3 us-gaap Other Inventory
OtherInventory
55000000
CY2021Q4 us-gaap Inventory Net
InventoryNet
546000000
CY2021Q3 us-gaap Inventory Net
InventoryNet
523000000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
113000000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
89000000
CY2021Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
111000000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1609000000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1425000000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1267000000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1376000000
CY2021Q4 us-gaap Goodwill
Goodwill
140000000
CY2021Q3 us-gaap Goodwill
Goodwill
140000000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
14000000
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
40000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
70000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100000000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
57000000
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
53000000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
158000000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000000
CY2021Q4 us-gaap Assets
Assets
3315000000
CY2021Q3 us-gaap Assets
Assets
3306000000
CY2021Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
72000000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
667000000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
35000000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
373000000
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
71000000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1147000000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
717000000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
73000000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
73000000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
279000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56723411
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56870237
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56579992
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56726818
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
57000000
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
143419
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
143419
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
4000000
CY2021Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
4000000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
11000000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
24000000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1049000000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1159000000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-319000000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-289000000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
794000000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
947000000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
154000000
CY2021Q3 us-gaap Minority Interest
MinorityInterest
143000000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948000000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1090000000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3315000000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3306000000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-80000000
CY2020Q4 us-gaap Profit Loss
ProfitLoss
70000000
CY2021Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39000000
CY2020Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39000000
CY2021Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
197000000
CY2021Q4 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-36000000
CY2020Q4 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2000000
CY2020Q4 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
6000000
CY2021Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1000000
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
6000000
CY2020Q4 us-gaap Share Based Compensation
ShareBasedCompensation
4000000
CY2021Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5000000
CY2020Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5000000
CY2021Q4 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
57000000
CY2020Q4 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
76000000
CY2021Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
95000000
CY2020Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37000000
CY2021Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27000000
CY2020Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10000000
CY2021Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9000000
CY2020Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
14000000
CY2021Q4 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3000000
CY2020Q4 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
7000000
CY2021Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-12000000
CY2020Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1000000
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49000000
CY2020Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21000000
CY2021Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30000000
CY2020Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000000
CY2021Q4 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-1000000
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000000
CY2020Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000000
CY2021Q4 us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
156000000
CY2020Q4 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
50000000
CY2021Q4 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5000000
CY2020Q4 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
66000000
CY2021Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
19000000
CY2020Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000000
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000000
CY2021Q4 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
8000000
CY2020Q4 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
1000000
CY2021Q4 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
21000000
CY2020Q4 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
20000000
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
103000000
CY2020Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-38000000
CY2021Q4 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-15000000
CY2020Q4 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
42000000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10000000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4000000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
170000000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151000000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180000000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
147000000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179000000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147000000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180000000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
147000000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1090000000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-80000000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28000000
CY2021Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.37
CY2021Q4 us-gaap Dividends
Dividends
21000000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6000000
CY2021Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
19000000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948000000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
814000000
CY2020Q4 us-gaap Profit Loss
ProfitLoss
70000000
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
96000000
CY2020Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.35
CY2020Q4 us-gaap Dividends
Dividends
20000000
CY2020Q4 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1000000
CY2020Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4000000
CY2020Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
2000000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
962000000
CY2021Q4 cbt Disposal Group Including Discontinued Operation Impairment Of Assets Held For Sale
DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssetsHeldForSale
197000000
CY2021Q4 cbt Disposal Group Including Discontinued Operation Adjusted Assets Held For Sale
DisposalGroupIncludingDiscontinuedOperationAdjustedAssetsHeldForSale
111000000
CY2021Q4 cbt Disposal Group Including Discontinued Operation Short Term Borrowings
DisposalGroupIncludingDiscontinuedOperationShortTermBorrowings
2000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
51000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Accrued Income Tax Payable
DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxPayable
1000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
37000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Inventory1
DisposalGroupIncludingDiscontinuedOperationInventory1
67000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
2000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
106000000
CY2021Q4 cbt Disposal Group Including Discontinued Operation Equity Affiliates
DisposalGroupIncludingDiscontinuedOperationEquityAffiliates
28000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Intangible Assets
DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
27000000
CY2021Q4 cbt Disposal Group Including Discontinued Operation Deferred Income Tax
DisposalGroupIncludingDiscontinuedOperationDeferredIncomeTax
31000000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Other Assets
DisposalGroupIncludingDiscontinuedOperationOtherAssets
10000000
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
308000000
CY2021Q4 cbt Disposal Group Including Discontinued Operation Long Term Debt
DisposalGroupIncludingDiscontinuedOperationLongTermDebt
17000000
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
71000000
CY2021Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
40000000
CY2021Q3 us-gaap Goodwill
Goodwill
140000000
CY2021Q4 us-gaap Goodwill
Goodwill
140000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
98000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
70000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
133000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
6000000
CY2021Q4 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">H. Contingencies</p> <p style="margin-top:4pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Respirator Liabilities</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabot has exposure in connection with a safety respiratory products business that a subsidiary acquired from American Optical Corporation (“AO”) in an April 1990 asset purchase transaction. The subsidiary manufactured respirators under the AO brand and disposed of that business in July 1995. In connection with its acquisition of the business, the subsidiary agreed, in certain circumstances, to assume a portion of AO’s liabilities, including costs of legal fees together with amounts paid in settlements and judgments, allocable to AO respiratory products used prior to the 1990 purchase by the Cabot subsidiary. In exchange for the subsidiary’s assumption of certain of AO’s respirator liabilities, AO agreed to provide to the subsidiary the benefits of: (i) AO’s insurance coverage for the period prior to the 1990 acquisition and (ii) a former owner’s indemnity of AO holding it harmless from any liability allocable to AO respiratory products used prior to May 1982. As more fully described in the 2021 10-K, the respirator liabilities generally involve claims for personal injury, including asbestosis, silicosis and coal worker’s pneumoconiosis, allegedly resulting from the use of respirators that are alleged to have been negligently designed and/or labeled. At no time did this respiratory product line represent a significant portion of the respirator market. In addition to Cabot’s subsidiary, other parties are responsible for significant portions of the costs of these respirator liabilities (as defined in the 2021 10-K, the “Payor Group”).</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabot has a reserve to cover its expected share of liabilities for pending and future respirator liability claims, which is included in Other liabilities and Accounts payable and accrued liabilities on the Consolidated Balance Sheets. The Company expects these liabilities to be incurred over a number of years. The reserve was $44 million at both December 31, 2021 and September 30, 2021. </p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s current estimate of the cost of its share of pending and future respirator liability claims is based on facts and circumstances existing at this time, including the number and nature of the remaining claims. Developments that could affect the Company’s estimate include, but are not limited to, (i) significant changes in the number of future claims, (ii) changes in the rate of dismissals without payment of pending claims, (iii) significant changes in the average cost of resolving claims, including potential settlements of groups of claims, (iv) significant changes in the legal costs of defending these claims, (v) changes in the nature of claims received or changes in our assessment of the viability of these claims, (vi) trial and appellate outcomes, (vii) changes in the law and procedure applicable to these claims, (viii) the financial viability of the parties that contribute to the payment of respirator claims, (ix) exhaustion or changes in the recoverability of the insurance coverage maintained by certain members of the Payor Group, or a change in the availability of the indemnity provided by a former owner of AO, (x) changes in the allocation of costs among the various parties paying legal and settlement costs, and (xi) a determination that the assumptions that were used to estimate Cabot’s share of liability are no longer reasonable. The Company cannot determine the impact of these potential developments on its current estimate of its share of liability for existing and future claims. Because reserves are limited to amounts that are probable and estimable as of a relevant measurement date, and there is inherent difficulty in projecting the impact of potential developments on Cabot’s share of liability for these existing and future claims, it is reasonably possible that the liabilities for existing and future claims could change in the near term and that change could be material.</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Insurance Recoveries - Pepinster, Belgium</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company’s Specialty Compounds manufacturing and research and development facility in Pepinster, Belgium experienced significant flooding. Full production is temporarily halted and is not expected to resume until the second quarter of fiscal 2022.  During fiscal 2021, the Company recorded expenses of $17 million for clean-up costs, inventory, and fixed asset impairments and simultaneously recognized a fully offsetting loss recovery from expected insurance proceeds.</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of fiscal 2022 the Company recorded additional expenses of $5 million for clean-up costs, inventory, and fixed asset impairments and simultaneously recognized a fully offsetting loss recovery from expected insurance proceeds as the Company expects insurance proceeds in excess of the total incurred costs and policy deductibles. The flood-related expenses and loss recovery are both included within Cost of sales in the Consolidated Statements of Operations for the first quarter of fiscal 2022.</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal 2021, the Company received insurance proceeds of $8 million.  During the first quarter of fiscal 2022, the Company received additional insurance proceeds of $5 million which is included in Cash provided by operating activities in the Consolidated Statements of Cash Flows for the first quarter of fiscal 2022. At both December 31, 2021 and September 30, 2021 the receivable for insurance recoveries was $9 million and is included in Accounts and notes receivable on the Consolidated Balance Sheet.</p> <p style="margin-top:4pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Matters</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has various other lawsuits, claims and contingent liabilities arising in the ordinary course of its business and with respect to its divested businesses. The Company does not believe that any of these matters will have a material adverse effect on its financial position; however, litigation is inherently unpredictable. Cabot could incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material impact on its results of operations in the period in which the amounts are accrued or its cash flows in the period in which the amounts are paid.</p>
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-12000000
CY2020Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000000
CY2021Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.13
CY2020Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.29
CY2021Q4 cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
-37000000
CY2020Q4 cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
2000000
CY2021Q4 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1000000
CY2020Q4 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1000000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-89000000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
60000000
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-89000000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
60000000
CY2021Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57700000
CY2020Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57200000
CY2021Q4 cbt Participating Securities
ParticipatingSecurities
900000
CY2020Q4 cbt Participating Securities
ParticipatingSecurities
700000
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56800000
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56500000
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-89000000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
60000000
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-89000000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
60000000
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56800000
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56500000
CY2020Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
100000
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56800000
CY2020Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56600000
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.06
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-89000000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
60000000
CY2021Q4 us-gaap Dividends Common Stock
DividendsCommonStock
21000000
CY2020Q4 us-gaap Dividends Common Stock
DividendsCommonStock
20000000
CY2021Q4 us-gaap Undistributed Earnings
UndistributedEarnings
-110000000
CY2020Q4 us-gaap Undistributed Earnings
UndistributedEarnings
40000000
CY2021Q4 cbt Undistributed Loss Earnings Allocated To Common Shareholders
UndistributedLossEarningsAllocatedToCommonShareholders
-110000000
CY2020Q4 cbt Undistributed Loss Earnings Allocated To Common Shareholders
UndistributedLossEarningsAllocatedToCommonShareholders
40000000
CY2021Q4 us-gaap Undistributed Earnings
UndistributedEarnings
-110000000
CY2020Q4 us-gaap Undistributed Earnings
UndistributedEarnings
40000000
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2356941
CY2020Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1305993
CY2021Q4 cbt Restructuring Charges Benefit
RestructuringChargesBenefit
2000000
CY2020Q4 cbt Restructuring Charges Benefit
RestructuringChargesBenefit
3000000
CY2021Q3 us-gaap Restructuring Reserve
RestructuringReserve
9000000
CY2021Q4 us-gaap Restructuring Charges
RestructuringCharges
2000000
CY2021Q4 cbt Payments For Proceeds From Restructuring
PaymentsForProceedsFromRestructuring
-2000000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
9000000
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1120000000
CY2021Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1130000000
CY2021Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021Q4 us-gaap Revenues
Revenues
968000000
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-93000000
CY2020Q4 us-gaap Revenues
Revenues
746000000
CY2020Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
99000000
CY2020Q4 cbt Percentage Of Sale Of Equity Method Affiliates
PercentageOfSaleOfEquityMethodAffiliates
1
CY2021Q4 us-gaap Revenues
Revenues
968000000
CY2020Q4 us-gaap Revenues
Revenues
746000000

Files In Submission

Name View Source Status
0001564590-22-003902-index-headers.html Edgar Link pending
0001564590-22-003902-index.html Edgar Link pending
0001564590-22-003902.txt Edgar Link pending
0001564590-22-003902-xbrl.zip Edgar Link pending
cbt-10q_20211231.htm Edgar Link pending
cbt-10q_20211231_htm.xml Edgar Link completed
cbt-20211231.xsd Edgar Link pending
cbt-20211231_cal.xml Edgar Link unprocessable
cbt-20211231_def.xml Edgar Link unprocessable
cbt-20211231_lab.xml Edgar Link unprocessable
cbt-20211231_pre.xml Edgar Link unprocessable
cbt-ex311_6.htm Edgar Link pending
cbt-ex312_9.htm Edgar Link pending
cbt-ex32_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending